Imipenem/relebactam

Edina Avdic, Pharm.D.
Pediatric Dosing Author: Lisa Hutchins, Pharm.D.

INDICATIONS

FDA

Infections caused by susceptible Gram-negative bacteria for patients who have limited or no alternative treatment options, who are ≥ 18 y/o; approval of these indications is based on limited clinical safety and efficacy data.
- Treatment of complicated urinary tract infections, including pyelonephritis (cUTI)
- Complicated intra-abdominal infections (cIAI)

NON-FDA APPROVED USES

MDR infections including bacteremia, pneumonia, osteomyelitis

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2025 Unbound Medicine, Inc. All rights reserved